HCAT vs. OPRA, MTTR, ZUO, MLNK, ENFN, VNET, COUR, FORTY, DCBO, and SABR
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Opera (OPRA), Matterport (MTTR), Zuora (ZUO), MeridianLink (MLNK), Enfusion (ENFN), VNET Group (VNET), Coursera (COUR), Formula Systems (1985) (FORTY), Docebo (DCBO), and Sabre (SABR). These companies are all part of the "computer software" industry.
Health Catalyst vs.
Health Catalyst (NASDAQ:HCAT) and Opera (NASDAQ:OPRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Opera has a net margin of 39.22% compared to Health Catalyst's net margin of -26.20%. Opera's return on equity of 19.22% beat Health Catalyst's return on equity.
Opera has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Opera, indicating that it is currently the more affordable of the two stocks.
Health Catalyst received 44 more outperform votes than Opera when rated by MarketBeat users. Likewise, 68.38% of users gave Health Catalyst an outperform vote while only 59.79% of users gave Opera an outperform vote.
In the previous week, Health Catalyst had 3 more articles in the media than Opera. MarketBeat recorded 12 mentions for Health Catalyst and 9 mentions for Opera. Opera's average media sentiment score of 0.46 beat Health Catalyst's score of 0.09 indicating that Opera is being referred to more favorably in the news media.
Health Catalyst has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Opera has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 10.2% of Opera shares are owned by institutional investors. 2.5% of Health Catalyst shares are owned by insiders. Comparatively, 84.4% of Opera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Health Catalyst presently has a consensus price target of $11.27, indicating a potential upside of 105.33%. Opera has a consensus price target of $24.75, indicating a potential upside of 35.39%. Given Health Catalyst's higher possible upside, research analysts clearly believe Health Catalyst is more favorable than Opera.
Summary
Opera beats Health Catalyst on 11 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
This page (NASDAQ:HCAT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free HCAT Stock Alerts